A multicentre double-blind, randomized parallel group study to evaluate the efficacy safety and tolerability of ezetimibe/simvastatin 10/40mg, atorvastatin 40mg, and rosuvastatin 10mg to Achieve an LDL-C [low-density lipoprotein-Cholesterol] Level of less than 2mmol/L in patients with established cardio vascular disease (CVD) or at 'High Risk' of Developing CVD Currently Treated With Simvastatin 40mg and With a Fasting LDL-C 2 Mmol/L

Trial Profile

A multicentre double-blind, randomized parallel group study to evaluate the efficacy safety and tolerability of ezetimibe/simvastatin 10/40mg, atorvastatin 40mg, and rosuvastatin 10mg to Achieve an LDL-C [low-density lipoprotein-Cholesterol] Level of less than 2mmol/L in patients with established cardio vascular disease (CVD) or at 'High Risk' of Developing CVD Currently Treated With Simvastatin 40mg and With a Fasting LDL-C 2 Mmol/L

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Atorvastatin; Rosuvastatin
  • Indications Cardiovascular disorders
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 29 Aug 2009 Results presented at ESC Congress 2009: Annual Congress of the European Society of Cardiology.
    • 29 Aug 2009 Primary endpoint 'Target achievement rate' has been met, according to results presented at ESC Congress 2009: Annual Congress of the European Society of Cardiology.
    • 12 Aug 2008 Actual study completion date (1 Jun 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top